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A randomized study was performed on 70 patients undergoing elective 
coronary bypass grafting to examine whether the combined infusion of the 
calcium channel blocker nifedipine (10/~g/kg per hour) and the 181-blocker 
metopropol (12 /~g/kg per hour, n = 34) reduces the prevalence of 
perioperative myocardial ischemia and arrhythmias. The control group 
received nifedipine alone (n = 36). In both groups the infusion was started 
from the onset of extracorporal circulation and maintained over a period of 
24 hours. Repeated 12-lead electrocardiographic and 3-channel Holter 
monitor ecordings for 48 hours were used to define perioperative myocar- 
dial ischemia (transient ischemic event, myocardial infarction) and ar- 
rhythmias (sinus tachycardia, supraventricular tachycardia, trial flutter/ 
fibrillation, ventricular tachycardia). Hemodynamic parameters were 
repeatedly assessed for 24 hours and serum enzyme levels (creatine kinase, 
MB isoenzyme of creatine kinase) for up to 36 hours after the operation. 
The two groups did not differ significantly with respect o preoperative 
anamnestic and surgical data. No signs of perioperative myocardial infarc- 
tion were detected in either group. However, a significantly lower incidence 
of transient ischemic episodes was observed in the nifedipine-metoprolol 
group than in the nifedipine group (3% vs l l%;p < 0.05). In addition, there 
was a tendency toward lower creatine kinase MB levels and peak values of 
creatine kinase and creatine kinase MB in the nifedipine-metoprolol group. 
With regard to perioperative arrhythmias, there was a significantly lower 
incidence of sinus tachycardia nd atrial flutter/fibrillation i the nifedip- 
ine-metoprolol group (9% and 6%) than in the nifedipine group (33% and 
27%, p < 0.05). In addition, postoperative heart rate was lower in the 
nifedipine-metoprolol group starting from the sixth hour after release of 
the aortic crossclamp (p < 0.05 and p < 0.01, respectively). No other 
hemodynamic parameters showed significant differences between the two 
groups and all returned to preoperative l vels within 24 hours. In conclu- 
sion, perioperative application of nifedipine and metoprolol in patients 
undergoing elective coronary bypass grafting reduces the prevalence of 
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perioperative myocardial ischemia and arrhythmias without significant 
negative inotropic effects. The combined infusion of the two drugs 
appears superior to nifedipine alone in preventing perioperative myo- 
cardial ischemia and reducing reperfusion-induced arrhythmias. 
(J THORAC CARDIOVASC SURG 1995;110:i461-9) 
improvements in perioperative patient manage- 
ment. Therefore, besides the technical quality of the 
surgical procedure, intraoperative and perioperative 
myocardial protection has become one of the most 
heavily discussed topics in cardiac surgery. 4-7 Vari- 
ous forms of intraoperative myocardial protection, 
such as systemic and local hypothermia, ntegrade 
and retrograde hypothermic crysta!!oid or blood 
cardioplegia, and warm blood cardioplegia, have 
been shown to be effective in experimental and 
clinical studies. 6'7 The quality of intraoperative 
myocardial protection certainly contributes to the 
preservation of functional integrity of the myocar- 
dium during the ischemic period. However, its in- 
fluence on the prevalence of myocardial ischemia 
and arrhythmias during the reperfusion period and 
the early postoperative period remains question- 
able. Consequently, adequate perioperative myocar- 
dial protection should include not only the intraop- 
erative but also the early postoperative period. 
In previous studies, we 8'9 have shown that the 
continuous perioperative infusion of the calcium chan- 
nel blocker nifedipine markedly reduces the preva- 
lence of early postoperative myocardial infarction and 
transient ischemia. These beneficial effects were 
mainly triggered by the profound efficacy of nifedipine 
as a coronary vasodilator, 1°' n because the dosages 
used had no measurable effect on perioperative hemo- 
dynamic parameters. 12'13 In a different study, we TM 
showed that the calcium channel blocker diltiazem is 
able to reduce both prevalence and extent of postop- 
erative myocardial ischemia, as well as supraventricu- 
lar and intraventricular arrhythmias. 
To further optimize the concept of perioperative 
antiischemic therapy, we conducted the current 
study to investigate whether a reduction of periop- 
erative oxygen demand by an additive perioperative 
infusion of the selective ]31-receptor antagonist 
metoprolol was able to potentiate the antiischemic 
efficacy of nifedipine. Metoprolol is known to re- 
duce myocardial oxygen consumption by decreasing 
heart rate and myocardial contractility, ls'16 In 
chronic coronary insufficiency (angina pectoris), as 
well as under circumstances of severe myocardial 
ischemia (myocardial infarction), the combination 
of metoprolol and nifedipine has already been 
proved to be of potent antiischemic efficacy] 5'17 
Furthermore, it is a goal of this study to provide 
evidence whether metoprolol has perioperative an- 
tiarrhythmic effects imilar to those of other ]3-blockers 
after coronary artery revascularization. 18' 19 
So that we could evaluate the perioperative 
antiischemic and antiarrhythmic potency of this 
drug combination, patients who received meto- 
prolol and nifedipine from the onset of extracor- 
poral circulation were compared with those re- 
ceiving nifedipine alone. In accordance with prior 
studies, perioperative myocardial ischemia was 
detected by means of a Holter monitor (Marquette 
Electronics (USA), Milwaukee, Wis.), serial assess- 
ment of changes in the electrocardiogram (ECG), and 
serum enzyme levels. 8' 9,14 The Holter monitor was 
used to evaluate the prevalence and characteristics of 
perioperative arrhythmias. 
Patients and methods 
The study was performed on 70 patients, randomly 
assigned to receive nifedipine (n = 36) or nifedipine 
and metoprolol (n = 34), all undergoing elective 
CABG. Patients with unstable angina, preoperative l ft 
or right bundle branch block, additional surgical or 
redo procedures, or a rethoracotomy necessitated by 
excessive postoperative bleeding were excluded. Two 
patients were excluded after the operation because of 
the need for reexploration to control bleeding (one in 
each group). None of the patients had a myocardial 
infarction less than 2 weeks before the operation. 
Catecholamine support was limited to low-dose intra- 
venous dopamine in eight patients of the mfedipine 
group and 12 patients of the combined rug regimen 
group. Intraaortic balloon pump support was not nec- 
essary in any of the patients in the study. All patients 
signed an informed consent form in accordance with the 
guidelines of the ethical committee of the University of 
Vienna. The last medications (nitrates, el-blockers or 
calcium antagonists) were given to the patients on the 
evening before the operation. 
Before the patient arrived in the operating room, 
premedication with 2 mg flunitrazepam was given orally. 
Anesthesia was then induced with etomidate, 0.2 to 0.3 
mg/kg, fentanyl, 0.005 to 0.007 mg/kg, and diazepam, 0.1 
to 0.3 mg/kg. Before intubation, a 0.1 mg/kg dose of 
pancuronium was administered. Anesthesia was main- 
tained with oxygen/nitrous oxide, fentanyl, diazepam, nd 
pancuronium. Artificial ventilation was used throughout 
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the operation and for at least 6 hours thereafter at a rate 
of 12 breaths/min and a tidal volume of 10 to 12 ml/kg. St. 
Thomas' Hospital cardioplegic solution (via the aortic 
root), systemic hypothermia (29°C rectal temperature), 
and topical cooling were used for intraoperative myocar- 
dial protectio n. The nifedipine group had a continuous 
intravenous nifedipine infusion (minimum dose 10/zg&g 
per hour) from the onset of extracorporal circulation until 
24 hours after release of the aortic crossclamp, whereas 
patients assigned to the combination drug group had 
continuous intravenous infusion of metoprolol (continu- 
ous dose 12 /zg/kg per hour) and nifedipine (minimum 
dose 10/xg/kg per hour). In case of hypertensive episodes, 
the nifedipine dosage was increased for patients in both 
groups to a maximum of 20/xg/kg per hour. This action 
was necessary in 15 patients of the nifedipine group and in 
13 patients of the combined rug group. The metopro!ol 
infusion was held constant throughout the study. No case 
of severe hypotension induced by either nifedipine or 
metoprololwas encountered. 
Hemodynamic measurements. Arterial pressure was 
continuously recorded via a radial artery cannula, and 
pulmonary ;artery pressure was measured by a Swan-Ganz 
catheter (Baxter Healthcare Corp., Edwards Div., Santa 
Ana, Calif.) inserted percutaneously into the pulmonary 
artery via the jugular vein. Pulmonary artery wedge, 
central venous, and left atrial pressures (measured with a 
catheter inserted uring the operation), as well as cardiac 
output (Edwards 9520A thermodilution computer), were 
assessed immediately before the operation (except left 
atrial pressure) and repeatedly thereafter up to 24 hours 
after release of the aortic crossclamp. From these data, 
pulmonary arterial resistance and cardiac index were 
calculated by means of standard formulas. 
Holter monitor and ECG recordings. As previously 
described, perioperative ECG changes were analyzed in 
two ways ' 9. 14. 
Continuous recording with a 3-channel Holter monitor. 
Monitoring began 2 hours after release of the aortic 
crossclamp in the intensive care unit and lasted for 48 
hours (Marquette Holter Recorder, Series 8500). Chan- 
nels 1 to 3 Corresponded to ECO leads V2, V5, and aV F. 
All tapes were evaluated without knowledge of the pa- 
tient's group assignment on a Marquette Laser Holter XP 
device by the same investigator. 
Besides ST-segment analysis, the tapes were screened 
for perioperative arrhythmias defined as follows: sinus 
tachycardia 4 period of greater than 130 beats/min originat- 
ing from the sinus node; supraventricular tachycardia: 
paroxysmal or  sustained supraventricular t chycardia; trial 
flutter or atrial fibrillation; ventricular tachycardia: more than 
three consecutive ventricular premature depolarizations. 
Twelve-lead ECG recording. A 12-lead ECG recording 
was obtained immediately before the operation. After the 
operation, ECG recordings were made repeatedly during 
the first 36 postoperative hours (in parallel with biochem- 
ical analyseg), as well as on every other day until the tenth 
postoperative day. 
Two different forms of perioperative myocardial isch- 
emia were defined by a combined analysis of ECG and 
Holter monitor recordings according to the following 
criteria: transient ischernic event: horizontal or downslop- 
Table I. Preoperative clinical data 
Nifedipine and 
Variable metoprolol NiJedipine 
No. of patients 34 36 
Male 31 (91%) 33 (92%) 
Female 3 (9%) 3 (8%) 
Age (yr) 61 _+ 8 58 _+ 8 
Two-vessel disease 6 (18%) 6 (17%) 
Three-vessel disease 28 (82%) 30 (83%) 
Left main stenosis 5 (15%) 6 (17%) 
Anterolateral MI 10 (29%) 7 (19%) 
Posterior MI 14 (41%) 19 (53%) 
NYHA functional class 
I or II 12 (35%) 14 (39%) 
III or IV 22 (65%) 22 (61%) 
Preoperative therapy 
Nifedipine 15 (44%) 18 (50%) 
/3-Blocker 9 (26%) 11 (31%) 
MI, Myocardial infarction; NYHA, Near York Heart Association. 
ing ST-segment depression of 1 mm or more and lasting at 
least 1 minute, measured 60 to 80 msec from the J point 
in at least one Holter channel with no signs of evolving 
myocardial infarction; myocardial infarction: (1) persistent 
typical ST-segment elevation of 2 mm or more, measured 
60 to 80 msec from the J point in at least one Holter 
channel, and development ofa new Q wave (>0.04 second 
in duration and less than one fourth of the following R 
wave in amplitude) in the corresponding 12-lead ECG 
after 10 days or during the 36-hour observation period 
after the operation; (2) persistent negative coronary T 
wave of more than 3 mm in a 12-lead ECG during the 
36-hour postoperative observation period or 10 days after 
the operation without the occurrence of a new Q wave. 
Biochemical analysis. Creatine kinase (CK) and the 
MB isoenzyme of CK (CK-MB) were assessed by enzy- 
matic fluorometric methods immediately before the oper- 
ation and 1, 2, 4, 6, 8, 12, 16, 20, 24 and 36 hours after 
release of the aortic crossclamp. 
Statistical analysis. Data in all tables are presented as 
mean + standard eviation. The raw data for each point 
in time and the peak value of each parameter within a 
patient were used for the analysis. An unpaired t test was 
used to compare groups of data. Fisher's exact test was 
used for comparison of baseline categoric (anumeric) 
factors. An analysis of variance for repeated measures on 
hemodynamic and enzyme data was performed. The Bon- 
ferroni t test was used to compare values at different 
points in time with each other. For all results, the 95% and 
99% levels for statistical significance were adopted. 
Results 
Table I shows preoperat ive data such as number  
of patients, age, sex, severity of coronary artery 
disease, history of infarction, New York  Heart  As- 
sociation classification, and preoperat ive therapeu-  
tic drug regimen. A t test showed no statistical 
differences between the t reatment  group receiving 
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Table II. Surgical data 
Nifedipine and 
Variable metoptvlol Nifedipine 
No. of patients 34 36 
ACC time (min) 53 _+ 14 57 _+ 21 
ECC time (min) 101 _+ 23 106 _+ 41 
No. of grafts/patient 3.45 3.58 
No. of ITA grafts 24 28 
Endarterectomy 5 6 
Mortality 0 0 
ACC, Aortic crossclamp; ECC, extracorporal circulation, ITA  internal 
thoracic artery. 
nifedipine and metoprolol and the group receiving 
nifedipine alone. In addition, both groups were 
sufficiently matched with regard to preoperative 
nifedipine- or /3-blocker treatment. Surgical data 
such as aortic crossclamp time, bypass time, number 
of vein grafts, and number of internal thoracic artery 
grafts are depicted in Table II. The analysis howed 
that the data were equally matched between the two 
groups without any statistically significant differ- 
ence. No death occurred during hospitalization or 
within 30 days after the operation in the two groups. 
Hemodynamics. Preoperative and postoperative 
hemodynamic parameters of both groups were ana- 
lyzed by analysis of variance for repeated measures 
(Table III). No statistically significant difference in 
perioperative hemodynamic parameters was de- 
tected between the two treatment groups except for 
one: heart rate was significantly lower in the nife- 
dipine-metoprolol group (Fig. 1) than in the nife- 
dipine group, starting from the sixth hour after 
release of the aortic crossclam p. However, none of 
the patients required transient cardiac pacing to 
control substantial bradycardia (<55 beats/min) 
combined with unstable hemodynamic conditions 
while being weaned from cardiopulmonary b pass 
or during the postoperative course. All other hemo- 
dynamic parameters eturned to preoperative l vels 
within 24 hours. 
ECG and Holter monitor recordings (Table IV). 
No patient in either group had a perioperative 
myocardial infarction. However, transient ischemic 
events were significantly less prevalent in the group 
receiving the combined rug regimen (3%) than in 
the nifedipine group (11%, p < 0.05). The periop- 
erative infusion of nifedipine and metoprolol led to 
a substantial decrease in the prevalence of sinus 
tachycardia (9% vs 33%) and atrial fibrillation or 
flutter (6% vs 27%, p < 0.05) as compared with the 
prevalence in the nifedipine group. However, no 
difference was detected between the two groups with 
regard to the occurrence of supraventricular and 
ventricular tachycardia. 
Myocardial enzymes. Fig. 2 presents perioperative 
CK-MB levels. These levels tended to be lower in the 
combined rug group throughout the 36-hour obser- 
vation period. At 4 hours after release of the aortic 
crossclamp, CK-MB values were significantly lower. 
However, at any other time the difference between the 
two groups did not reach statistical significance. Table 
V depicts peak values of CK and CK-MB enzymes. 
Peak values for both enzymes were slightly but insig- 
nificantly lower in the metoprolol-nifedipine group 
than in the nifedipine group. 
Discussion 
The combination of fl-blockers and calcium chan- 
nel blockers has already been shown to lessen the 
effects of ischemia under experimental conditions of 
myocardial ischemia, ° The results of the present 
study demonstrate not only that the combined rug 
regimen of metoprolol and nifedipine is feasible in 
patients undergoing CABG, without inducing rele- 
vant hemodynamic problems, but also that it is even 
more effective in decreasing perioperative myocar- 
dial ischemia and reducing arrhythmias than the 
perioperative infusion of nifedipine alone. 
Several possible pathophysiologic mechanisms 
may explain the potent antiischemic efficacy of 
nifedipine in combination with metoprolol in pa- 
tients undergoing CABG procedures. 
The potent coronary vasodilator nifedipine has 
been reported to increase myocardial blood flow, 
particularly in the subendocardium. This mechanism 
may be partly responsible for its antiischemic po- 
tency.10.21, 22On the other hand, experimental nd 
clinical studies suggest hat an additional mecha- 
nism may account for the antiischemic effects of 
nifedipine. Various factors like stress, exercise, or 
anesthesia activate the sympathetic nervous ystem, 
which among many other mechanisms also stimu- 
lates coronary ~2-receptors via the physiologic neu- 
rotransmitter norepinephrine. Especially under con- 
ditions of myocardial ischemia, activated coronary 
~2-receptors induce additional, significant coronary 
vasoconstriction. Nifedipine is a functional antago- 
nist of o~2-receptor-mediated sympathetic coronary 
vasoconstriction a d thereby reduces coronary vas- 
cular resistance, primarily under conditions of se- 
vere myocardial ischemia. 1°' 23 
In contrast to coronary O~a-receptors , which have a 
direct influence on the regulation of myocardial 
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Fig. 1. Perioperative changes in heart rate.pOP, Preoperative; 1-24h mark the hours after opening of the 
aortic crossclamp. Data are given as mean _+ standard eviation. Values differ significantly from that for 
nifedipine-metoprolol group (*p < 0.05, **p < 0.01). 
Table IIL Hernodynamic data 
Preoperative One hour Eight hours Sixteen hours Twenty-four hours 
Variable N4 M N N+M N N+M N N+M N N+M N 
Mean arterial 73.8 ± 5.3 71.2 _+ 6.7 66.3 _+ 8.9 67.2 ± 7.3 74.8 ± 6.1 75.9 _+ 5.9 73.4 ± 4.8 75.8 ± 4.4 83.2 _+ 4.8 82.1 ± 5.1 
pressure 
(mm Hg) 
Left atrial pres- - -  - -  7.4 ± 2.2 
sure (mm Hg) 
Central venous 8.5 ± 3.6 9.2 + 3.8 8.9 _+ 3.5 
pressure 
(mm Hg) 
Mean pulmonary 
artery pressure 
(mm Hg) 
Pulmonary arterial 
resistance (U) 
Cardiac index 
(L/min/m 2) 
17.4-+4.9 18.3+--5.9 16.4±4.4 
7 .1±1.9  8.6-+1.1 8 .8±0.8  9.1 +1.3 9.0--+0.7 9 .2±2.1  9.4--+0.9 
9.3--+4.0 8 .6±3.2  8 .6±3.7  8.8--+4.8 8 .1±4.7  8.4--+4.7 8 .3±4.3  
16.8±4.5 18.3--+3.3 17.1+4.2 18.3±4.9 16.3--+4.9 17.9±5.9 17.3--+4.9 
4.5--+2.3 4 .7± 1.6 3 .7±1.6  4.0--+1.5 4.5 +1.5  4.1--+1.4 3.8--+1.2 3 .5±1.6  3.6--+1.5 3.3 +0.8  
2.2--+0.5 2.3 +0.6  2 .4±0.6  2.5--+0.7 2.2 +0.5  2.4--+0.7 2.6--+0.4 2 .8±0.7  2.6--+0.5 2 .8±0.5  
Hemodynamic parameters before and for 24 hours after opening of the aortic crossclamp. N+M, Nifedipine plus metoprolol group (n = 34); N, nifedipine 
group (n = 36)~ U, arbitrary unit. 
perfusion in poststenotic areas, an activation of 
myocardia~/31-receptors produces no physiologically 
or pathoplaysiologically relevant coronary dilatation. 
Consequefitly, the rationale for using /31-receptor 
blockers such as metoprolol in the prevention of 
perioperative myocardial ischemia is its efficacy in 
decreasing lmyocardial oxygen consumption and the 
resulting improvement of the oxygen supply/demand 
ratio. Two basic mechanisms mediated by/31-rece p-
tors should be mentioned that may account for their 
additional antiischemic potency when administered 
in combination with a calcium channel blocker such 
as nifedipine. 
The negative chronotropic effect of /31-blockers 
causes an indirect antiischemic effect by reducing 
heart rate. Heart rate reduction leads to a prolon- 
gation of diastole, the phase during the cardiac ycle 
that is mainly responsible for beat-to-beat coronary 
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Table IV. Perioperative myocardial ischemia nd 
arrhythmias 
Nifedipine and p 
Variable metoprolol Nifedipine Value 
Transient ischemic event 1 (3%) 4 (11%) <0.05 
Myocardial infarction 0 0 NS 
Sinus tachycardia 3 (9%) 12 (33%) <0.05 
Supraventricular tachycardia 1 (3%) 2 (6%) NS 
Atrial flutter and/or fibrillation 2 (6%) 10 (27%) <0.05 
Ventricular tachycardia 2 (6%) 0 NS 
NS, Not significant. 
perfusion. 24 Although we could not directly measure 
it, a reduction in heart rate during the perioperative 
period may also improve myocardial perfusion. 25 
The negative inotropic effect of /31-blockers de- 
creases the oxygen consumption of a normally per- 
fused area located near a hypoperfused area and, 
consequently, prevents the development of a steal 
phenomenon, which leads to a supplementary dam- 
age to the hypoperfused area. 26 Furthermore, a 
reduction of oxygen demand in the hypoperfused 
area also optimizes the local oxygen distribution 
balance, z°
In this randomized study perioperative myocar- 
dial ischemia was detected by postoperative 48-hour 
Holter monitor ecordings, erial assessment of 12- 
lead ECGs, analysis of myocardial enzymes, and 
continuous hemodynamic monitoring. The analysis 
of postoperative ST-segment changes, recorded by 
3-channel Holter monitors, has become a widely 
used noninvasive method for the detection of myo- 
cardial ischemic events. The sensitivity of these 
recordings is comparable with that of exercise 
ECGs. By using the strict diagnostic riteria of 
combined analysis of Holter monitor ecordings and 
12-lead ECGs, we avoided misinterpreting ST- 
segment changes throughout he postoperative 
period--electrode imbalance, temperature changes, 
history of myocardial infarction, and postoperative 
pericarditis. 
According to the diagnostic riteria used in the 
study, no patient in either group had a perioperative 
myocardial infarction. In contrast, the analysis pro- 
vided evidence that nifedipine and metoprolol as a 
combined rug regimen significantly reduced the prev- 
alence of postoperative transient ischemic events in 
comparison with nifedipine alone (3% vs 11%). 
Although the clinical importance of perioperative 
supraventricular arrhythmias nd their contribution 
to the occurrence of postoperative ischemia or other 
complications appear to be insignificant, such ar- 
rhythmias are frequently not well tolerated by the 
patients and may induce various symptoms such as 
temporary hemodynamic nstability, shortness of 
breath, or chest discomfort. Consequently, pharma- 
cologic prevention of perioperative arrhythmias 
should be mandatory during postoperative treat- 
ment in the intensive care unit. In this study, the 
substantially ower incidence of supraventricular ar-
rhythmias ( inus tachycardia and atrial fibrillation or 
flutter) in the nifedipine-metoprolol group as com- 
pared with the nifedipine group must be evaluated 
with respect to the documented antiarrhythmic effi- 
cacy of the /3-blocker metoprololS Because an 
almost equal number of patients in both groups had 
preoperative treatment with /3-blockers, it appears 
obvious that the perioperative infusion of metopro- 
lol in the combined rug regimen group rather than 
use of preoperative /3-blocker medication was re- 
sponsible for the low incidence of arrhythmias in
this group. There was no difference between the two 
groups with regard to the occurrence of ventricular 
tachycardia. Ventricular tachycardia is often trig- 
gered by significant myocardial ischemia or is the 
cause of ischemia. Thus the low incidence of ven- 
tricular tachycardia in both groups is in accord with 
the overall low incidence of manifestations of severe 
myocardial ischemia, such as myocardial infarction. 
Analyses of serum enzymes ensitive for myocar- 
dial ischemia did not show any statistically signifi- 
cant differences between the two treatment groups. 
CK values were almost identical; both single and 
peak CK-MB values were only slightly lower in the 
metoprolol-nifedipine group than in the nifedipine 
group over the 36-hour observation period. The 
similar perioperative nzyme levels in the two 
groups may be explained by the fact that periopera- 
tive myocardial infarction iscorrelated with irrevers- 
ible cell damage and high enzyme levels, 28 whereas 
transient ischemic events do not produce significant 
necrosis and higher enzyme levels. Because the two 
groups differed only with respect to the incidence of 
transient ischemic events, the enzyme analysis was 
unable to detect he lower incidence of periopera- 
tive myocardial ischemia in the metoprolol-nifedip- 
ine group. In addition, our earlier studies how that 
with nifedipine alone, perioperative enzyme plasma 
levels are already much lower than those of control 
groups treated with nitroglycerin, even in patients 
without any sign of myocardial ischemia on ECG or 
Holter monitor tracings. 8'9 Consequently, the com- 
bined therapeutic regimen with metoprolol and 
nifedipine may have reached the pharmacologic and 
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Fig. 2. Perioperative serum creatine kinase-MB levels before the operation (pOP) and for 36 hours after 
opening of the aortic crossclamp. MB, MB isoenzyme of creatine kinase; Data are given as mean _+ 
standard eviation. Value differs ignificantly from that for nifedipine-metoprolol group (*p < 0.05). 
therapeutic limits in the prevention of perioperative 
myocardial ischemia. 
The decrease in the prevalence of transient isch- 
emic events in the metoprolol-nifedipine group in 
comparison with the nifedipine only group can be 
explained by the metoproloMnduced reduction of 
heart rate, starting 6 hours after release of the aortic 
crossclamp. All other perioperative hemodynamic, 
surgical (eg., aortic crossclamp time, bypass time, 
number of distal anastomoses), or preoperative clin- 
ical data (e.g., age, sex, severity of coronary artery 
disease, history of myocardial infarction) predicting 
the occurrence of perioperative myocardial ischemia 
were sulficiently matched between the groups and 
did not influence the results of the study. The 
metoproloi-induced reduction in heart rate should 
account for a decrease in myocardial oxygen de- 
mand and a further increase in oxygen supply by 
increasing blood flow to the endocardium, especially 
in critically perfused areas. Consequently, it should 
lead to a further reduction in the prevalence of 
myocardial ischemia. 24' 25 
Whereas, the continuous infusion of low-dose meto- 
prolol (12 pg/kg per hour) was able to provide a 
substantial negative chronotropic effect, the hemody- 
namic data show no indication of profound negative 
inotropic activity of metoprolol: because hemody- 
namic parameters indirectly indicative of depressed 
myocardial contractility, such as cardiac index, mean 
Table V. Enzyme data (IU/ml) 
Nifedipine and 
Variable metoprolol Nifedipine 
CK max 388 -+ 41 418 _+ 47 
CK-MB max 15.7 _+ 3.1 18.7 4- 3.9 
aortic pressure, and left atrial pressure, were only 
slightly lower in the combined rug regimen group 
throughout the 24-hour observation period, the nega- 
tive inotropic effect of metoprolol may have been 
negligible and, consequently, cannot account for the 
additional antiischemic efficacy of the combined regi- 
men. However, metoprolol should not be infused in 
higher dosages that exert not only negative chrono- 
tropic effects but also substantial negative inotropic 
effects. 29 A marked depression of myocardial contrac- 
tility may induce heart failure or the need for cate- 
cholamine or mechanical support, especially in pa- 
tients with severely depressed myocardial function. 
In conclusion, this randomized study with contin- 
uous perioperative infusion of nifedipine and meto- 
prolol versus nifedipine alone provides evidence 
that the combined regimen is able to minimize the 
incidence of perioperative myocardial ischemia nd 
arrhythmias. Whereas the immediate clinical value 
of the additional, metoprolol-induced reduction of 
perioperative transient ischemic events remains un- 
clear, the reduction in reperfusion-induced arrhyth- 
1 4 6 8 Podesser et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1995 
mias certainly improves the perioperative clinical 
situation of the patient and should be considered as 
an important goal for postoperative treatment. 
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Discussion 
Dr. Roland Fasol (Bad Neustadt~SaMe, G rmany). It is 
indeed an interesting approach to down-regulate the 
perioperative myocardial oxygen demand by decreasing 
the pulse/pressure rate and simultaneously increasing 
oxygen supply to the heart with this drug combination. 
I congratulate you on your results of achieving signifi- 
cantly fewer perioperative arrhythmias and transient isch- 
emic events in your study group by applying this periop- 
erative regimen. 
I think it may be assumed that a group of patients with 
fewer or no arrhythmias and ischemic events after CABG 
may consequently recover more quickly and require fewer 
additional therapeutic nterventions. This may thus contrib- 
ute to efforts of improving cost efficiency in cardiac surgery. 
Can you comment on the safety of applying/3-block- 
ers in patients with severely depressed myocardial 
function? Have you assessed the aspects of cost effi- 
ciency in regard to your clinical results of applying 
additional calcium antagonists and /3-blockers in your 
group of patients? 
Dr. Podesser. Thank you very much for your question, 
Dr. Fasol. It is always crucial to combine a low ejection 
fraction with a/3-blocker. Fortunately, we had no patients 
with an ejection fraction less than 30% in this study. 
However, in such a case, close hemodynamic monitoring 
would be necessary while you use this regimen. 
Concerning your second question, I would like to stress 
that we did not assess cost efficiency when we designed 
this study. I think you are right that this regimen might 
reduce the stay of the patient in the intensive care unit 
owing to arrhythmias and thereby produce more cost 
efficiency. On the other hand, the number of patients is 
too small to give real facts on this particular question. 
